
Common name
isopropyl 2-hydroxy-2-methyl-propanoate
IUPAC name
isopropyl 2-hydroxy-2-methyl-propanoate
SMILES
C(C)(C)(C(=O)OC(C)C)O
Common name
isopropyl 2-hydroxy-2-methyl-propanoate
IUPAC name
isopropyl 2-hydroxy-2-methyl-propanoate
SMILES
C(C)(C)(C(=O)OC(C)C)O
INCHI
InChI=1S/C7H14O3/c1-5(2)10-6(8)7(3,4)9/h5,9H,1-4H3
FORMULA
C7H14O3

Common name
isopropyl 2-hydroxy-2-methyl-propanoate
IUPAC name
isopropyl 2-hydroxy-2-methyl-propanoate
Molecular weight
146.184
clogP
0.486
clogS
-0.618
Frequency
0.0003
HBond Acceptor
3
HBond Donor
1
Total PolarSurface Area
46.53
Number of Rings
0
Rotatable Bond
3
Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
---|---|---|---|---|
FDBD00891 | Fenofibrate |
![]() |
Anticholesteremic Agents; Hypolipidemic Agents; Lipid Modifying Agents, Plain; Lipid Modifying Agents; Cardiovascular System; Fibrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C8 Inducers; CYP3A4 Inhibitors; | For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). |
1 ,
1
FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
---|---|---|---|---|---|
1g37_ligand_3_50.mol2 | 1g37 | 1 | -5.51 | C[C@@H](C(=O)OCC)O | 8 |
3e3c_ligand_3_36.mol2 | 3e3c | 0.818182 | -6.10 | C[C@@H](O)COC(=O)C | 8 |
4xpj_ligand_3_404.mol2 | 4xpj | 0.818182 | -5.35 | [C@H](O)(C)COC(=O)C | 8 |
1p6d_ligand_4_1325.mol2 | 1p6d | 0.8 | -6.51 | C(OC(=O)CC)(C)C | 8 |
1p6e_ligand_4_671.mol2 | 1p6e | 0.8 | -6.42 | CC(C)OC(=O)CC | 8 |
1p6d_ligand_3_395.mol2 | 1p6d | 0.8 | -6.18 | C(OC(=O)CC)C | 7 |
1p6e_ligand_3_244.mol2 | 1p6e | 0.8 | -6.12 | CCOC(=O)CC | 7 |
1p6d_ligand_3_350.mol2 | 1p6d | 0.8 | -6.09 | C(OC(=O)CC)C | 7 |
4tnw_ligand_3_158.mol2 | 4tnw | 0.8 | -5.99 | CCC(=O)OCC | 7 |
1p6e_ligand_3_208.mol2 | 1p6e | 0.8 | -5.97 | CCOC(=O)CC | 7 |
133 ,
14